1Kadowaki T, Shiozaki H, Inoue M, et al. E-cadherin and a-catenin expression in human esophageal cancer. Cancer Res, 1994, 54:291-296.
2Bussemarkers MJ, Bokhoven AV, Mees SG, et al. Molecular cloning and characterization of the human E-cadherin cDNA. Mol Bio Reports, 1993, 17:123-128.
3Lipponen PK, Eskelinen MJ. Reduced expression of E-cadherinis related to invasive disease and frequent recurrence in bladdercancer. J Cancer Res Clin Oncol, 1995, 121: 303-308.
4Shariat SF,Pahlavan S,Baseman AG,et al. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology, 2001, 57: 60-65.
6Kanayama H, Yokota K, Kurokawa Y, et al. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer, 1998, 82 : 1359-1366.
7Gohji K, Fujimoto N, Komiyama T, et al. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer, 1996, 78: 2379-2387.
8Gohji K, Fujimoto N, Ohkawa J, et al. Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br J Cancer, 1998, 77: 650-655.
3Szarvas T, Hoffmann F, Bedker M. Plasma E-cadherin levels in bladder cancer:does it improve risk stratification? [J]. Urologe A, 2011, 50(1):64 70.
4Putzke A P,Ventura A P,Bailey A M. Metastatic progression of prostate cancer and e-cadherin regulation by zebl and SRC family kinases[J]. Am J Pathol, 2011,179(1) :400 410.
5Bellmunt J, Petrylak D P. New therapeutic challenges in ad vancedbladdercancer[J]. Semin Oncol, 2012, 39 (5):598-607.
